0 136

Cited 0 times in

11C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11C-Methionine PET/CT in Glioma Classification and Survival Prediction

 Dongwoo Kim  ;  Ju Hyeon Yi  ;  Youngjoo Park  ;  Sun Jung Kim  ;  Seok-Gu Kang  ;  Se Hoon Kim  ;  Joong-Hyun Chun  ;  Jong Hee Chang  ;  Mijin Yun 
 CLINICAL NUCLEAR MEDICINE, Vol.49(2) : 109-115, 2024-02 
Journal Title
Issue Date
Acetates ; Astrocytoma* ; Brain Neoplasms* / diagnostic imaging ; Brain Neoplasms* / pathology ; Glioma* / diagnostic imaging ; Glioma* / pathology ; Gliosis ; Humans ; Inflammation ; Methionine ; Mutation ; Positron Emission Tomography Computed Tomography ; Prognosis ; Prospective Studies ; Racemethionine ; Tumor Microenvironment
Purpose: 11C-acetate (ACE) PET/CT visualizes reactive astrogliosis in tumor microenvironment. This study compared 11C-ACE and 11C-methionine (MET) PET/CT for glioma classification and predicting patient survival.

Patients and methods: In this prospective study, a total of 142 patients with cerebral gliomas underwent preoperative MRI, 11C-MET PET/CT, and 11C-ACE PET/CT. Tumor-to-contralateral cortex (TNRMET) and tumor-to-choroid plexus ratios (TNRACE) were calculated for 11C-MET and 11C-ACE. The Kruskal-Wallis test and Bonferroni post hoc analysis were used to compare the differences in 11C-TNRMET and 11C-TNRACE. The Cox proportional hazards regression analysis and classification and regression tree models were used to assess progression-free survival (PFS) and overall survival (OS).

Results: The median 11C-TNRMET and 11C-TNRACE for oligodendrogliomas (ODs), IDH1-mutant astrocytomas, IDH1-wildtype astrocytomas, and glioblastomas were 2.75, 1.40, 2.30, and 3.70, respectively, and 1.40, 1.20, 1.77, and 2.87, respectively. The median 11C-TNRMET was significantly different among the groups, except between ODs and IDH1-wildtype astrocytomas, whereas the median 11C-TNRACE was significantly different among all groups. The classification and regression tree model identified 4 risk groups (IDH1-mutant with 11C-TNRACE ≤ 1.4, IDH1-mutant with 11C-TNRACE > 1.4, IDH1-wildtype with 11C-TNRACE ≤ 1.8, and IDH1-wildtype with 11C-TNRACE > 1.8), with median PFS of 52.7, 44.5, 25.9, and 8.9 months, respectively. Using a 11C-TNRACE cutoff of 1.4 for IDH1-mutant gliomas and a 11C-TNRACE cutoff of 2.0 for IDH1-wildtype gliomas, all gliomas were divided into 4 groups with median OS of 52.7, 46.8, 27.6, and 12.0 months, respectively. Significant differences in PFS and OS were observed among the 4 groups after correcting for multiple comparisons.

Conclusions: 11C-ACE PET/CT is better for glioma classification and survival prediction than 11C-MET PET/CT, highlighting its potential role in cerebral glioma patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Kim, Dongwoo(김동우) ORCID logo https://orcid.org/0000-0002-1723-604X
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Yun, Mijin(윤미진) ORCID logo https://orcid.org/0000-0002-1712-163X
Chang, Jong Hee(장종희) ORCID logo https://orcid.org/0000-0003-1509-9800
Chun, Joong-Hyun(전중현) ORCID logo https://orcid.org/0000-0002-9665-7829
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.